NYSE · COO
Healthcare · Medical - Instruments & Supplies
$55.29
Up+$1.52 (+2.82%)
Updated Sep 20, 2026, 11:08 AM
SID Score
3.7/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
COO closed at $55.29 after 19 trading sessions, down 27.06% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $54.495 | $55.92 | $54.095 | $55.29 | 8.8M |
| Sep 17, 2026 | $54.82 | $54.82 | $52.78 | $53.775 | 5.71M |
| Sep 16, 2026 | $54.37 | $55.1165 | $53.92 | $54.61 | 5.31M |
| Sep 15, 2026 | $54.40 | $54.80 | $52.965 | $53.27 | 4.42M |
| Sep 14, 2026 | $54.78 | $54.99 | $53.595 | $54.22 | 5.41M |
| Sep 11, 2026 | $54.66 | $55.66 | $53.15 | $53.91 | 6.44M |
| Sep 10, 2026 | $51.875 | $55.43 | $51.01 | $54.17 | 18.65M |
| Sep 9, 2026 | $67.07 | $67.92 | $62.24 | $63.48 | 9.57M |
| Sep 8, 2026 | $68.55 | $68.99 | $67.59 | $67.69 | 2.93M |
| Sep 4, 2026 | $70.325 | $70.48 | $69.51 | $69.59 | 1.96M |
| Sep 3, 2026 | $69.78 | $70.68 | $69.09 | $70.64 | 2.1M |
| Sep 2, 2026 | $69.305 | $71.07 | $69.28 | $69.73 | 1.58M |
| Sep 1, 2026 | $70.255 | $70.80 | $69.075 | $69.28 | 1.36M |
| Aug 31, 2026 | $70.49 | $70.755 | $69.6374 | $70.09 | 2.16M |
| Aug 28, 2026 | $71.18 | $71.50 | $70.664 | $71.17 | 1.01M |
| Aug 27, 2026 | $71.90 | $72.08 | $70.70 | $70.96 | 1.52M |
| Aug 26, 2026 | $72.62 | $72.93 | $72.2201 | $72.68 | 1.56M |
| Aug 25, 2026 | $75.42 | $75.71 | $72.9214 | $73.04 | 1.43M |
| Aug 24, 2026 | $76.14 | $76.58 | $75.62 | $75.80 | 1.14M |
The latest Smart Investors Daily articles mentioning COO.
COO research
Company profile and research snapshot.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | Needham | Buy | — |
| Sep 11, 2026 | Mizuho | Outperform | — |
| Sep 10, 2026 | JP Morgan | Neutral | — |
| Sep 10, 2026 | Piper Sandler | Neutral | — |
| Sep 10, 2026 | Citigroup | Neutral | — |
Generated Sep 20, 2026, 11:13 AM
Cooper Companies stock rose 2.82% today as investors digest activist investor JANA Partners' aggressive campaign demanding CEO replacement and strategic restructuring. The market appears to be pricing in potential upside from operational changes, though the company faces significant pressure to demonstrate improved performance and capital allocation.
Bottom line: Cooper Companies faces a critical inflection point as activist JANA Partners demands leadership and strategic changes, with today's stock rise suggesting investors see opportunity in potential operational improvements. The key watch will be whether the board acts decisively on the CEO search and capital allocation strategy, as delays or half-measures could reignite investor frustration and renewed selling pressure.
Yahoo · Sep 18, 2026
As Cooper Companies has lagged behind its industry peers over the past year, Wall Street analysts maintain a cautious outlook on its prospects.
Benzinga · Sep 18, 2026
Activist firm Jana Partners calls for leadership overhaul and asset sales at Cooper Companies (COO) amid governance concerns.
Yahoo · Sep 18, 2026
Cooper Cos. stock rises as activist investor Jana Partners calls for the company to search for a new CEO and sell a key business segment.
Yahoo · Sep 18, 2026
In September 2026, The Cooper Companies completed a broad strategic review, ultimately deciding to retain CooperSurgical after assessing potential sale offers, while also outlining revised capital allocation plans and operational initiatives for CooperVision and CooperSurgical. The Board cited temporary factors such as a new competitor in non-hormonal IUDs and the impact of recent fertility litigation settlements as reasons for a perceived valuation gap that made selling CooperSurgical less...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COO.
